[go: up one dir, main page]

US20010014352A1 - Compressed tablet formulation - Google Patents

Compressed tablet formulation Download PDF

Info

Publication number
US20010014352A1
US20010014352A1 US09/312,617 US31261799A US2001014352A1 US 20010014352 A1 US20010014352 A1 US 20010014352A1 US 31261799 A US31261799 A US 31261799A US 2001014352 A1 US2001014352 A1 US 2001014352A1
Authority
US
United States
Prior art keywords
compressed tablet
recited
mixture
efavirenz
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/312,617
Inventor
Udit Batra
Raymond J. Higgins
Ashok V. Katdare
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/312,617 priority Critical patent/US20010014352A1/en
Priority to US09/894,921 priority patent/US7060294B2/en
Publication of US20010014352A1 publication Critical patent/US20010014352A1/en
Priority to US11/404,357 priority patent/US7595063B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes

Definitions

  • This invention relates to a compressed tablet formulation for efavirenz, which is 50 percent by weight drug loaded and can optionally be film coated.
  • Efavirenz is a non-nucleoside reverse trancriptase inhibitor being studied clinically for use in the treatment of HIV infections and AIDS.
  • a process for the manufacture of the compressed tablet is also disclosed.
  • the compressed tablet is an improved formulation which allows one to utilize a tablet over a capsule.
  • the compressed tablet has been demonstrated to have comparable bioavailability data to that seen with the capsule.
  • the key feature of the formulation is the use of a superdisintegrant and disintegrant intragranularly to achieved a bioequivalent formulation.
  • the compressed tablet form was difficult to manage as efavirenz is fragile and the drug loses crystallinity upon compression. This was overcome by adding lactose extragranularly.
  • the instant invention relates to a compressed tablet of efavirenz which is a 50 percent drug loaded formulation.
  • the instant invention also relates to the process for manufacture of the compressed tablet using a wet granulation method.
  • the instant invention relates to a compressed tablet of efavirenz formulation which is 50 percent by weight drug loaded and can optionally be film coated.
  • the compressed tablet comprises: efavirenz, filler/disintegrant, superdisintegrant, binder, surfactant, filler/compression aid, lubricant, and solvent, wherein of efavirenz is about 50% by weight of the total composition of the compressed tablet.
  • the efavirenz concentration can be varied from about 1 to about 75 % by changing the concentration of remaining excipients. Furthermore, changing the tooling can give a wide ranges of doses, e.g. a 20 mg dose in a 40 mg tablet, a 300 mg dose in a 600 mg tablet, or a 600 mg dose in a 1200 mg compressed tablet, with the same composition. Removing the lactose from the formulation gives about 70% drug in the formulation giving a 600 mg dose in a 860 mg compressed tablet. These variations are very straightforward to effect.
  • This formulation will allow one to formulate efavirenz as a single 600 mg dose as an 860 mg compressed tablet, where as a capsule formulation requires the administration of at least two capsules to dose with 600 mg of efavirenz.
  • the invention contemplates the use of any pharmaceutically acceptable fillers/compression aids, disintegrants, super-disintegrants, lubricants, binders, surfactants, film coatings, and solvents. Examples of these components are set forth below and are described in more detail in the Handbook of Pharmaceutical Excipients, Second Edition, Ed. A. Wade and P. J. Weller, 1994, The Pharmaceutical Press, London, England.
  • Fillers and compression aid concentrations can be varied between about 5% to about 80% to complement the drug amount.
  • fillers/compression aids include: lactose, calcium carbonate, calcium sulfate, compressible sugars, dextrates, dextrin, dextrose, calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin mannitol, powdered cellulose, pregelatinized starch, and sucrose.
  • disintegrants include: alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, colloidal silicon dioxide, croscarmellose sodium, crospovidone, guar gum, magnesium aluminum silicate, methylcellulose, microcrystalline cellulose, polyacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate and starch.
  • fillers also referred to as a diluent
  • examples of fillers include: calcium carbonate, calcium sulfate, compressible sugars, confectioner's sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, glyceryl palmitostearate, hydrogenated vegetable oil (type I), kaolin, lactose, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates, potassium chloride, powdered cellulose, pregelatinized starch, sodium chloride, sorbitol, starch, sucrose, sugar spheres, talc and tribasic calcium phosphate.
  • Superdisintegrant concentration can be varied between about 1% to about 20% to complement the drug amount and obtain reasonable dissolution.
  • examples of super-disintegrants include the disintegrants listed above, carboxymethylcellulose sodium, croscarmellose sodium, povidone, guar gum, polacrilin potassium, and pregelatinized starch.
  • Binder concentration can be varied between 1 and 10% to complement the drug amount.
  • binders include: acacia, alginic acid, carbomer, carboxymethylcellulose sodium, dextrin, ethylcellulose, gelatin, guar gum, hydrogenated vegetable oil (type I), hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, liquid glucose, magnesium aluminaum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone, pregelatinized starch, sodium alginate, starch, and zein.
  • surfactants comprises anionic and cationic surfactants, such as sodium lauryl sulfate, docusate sodium (dioctyl sulfosuccinate sodium salt), benzalkonium chloride, benzethonium chloride, and cetrimide (alkyltrimethylammonium bromide, predominantly C 14 alkyl).
  • anionic and cationic surfactants such as sodium lauryl sulfate, docusate sodium (dioctyl sulfosuccinate sodium salt), benzalkonium chloride, benzethonium chloride, and cetrimide (alkyltrimethylammonium bromide, predominantly C 14 alkyl).
  • Examples of lubricants include: calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, light mineral oil, magnesium stearate, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc and zinc stearate.
  • solvent comprises: water, ethanol or mixtures thereof.
  • the compressed tablet can also be film coated.
  • Film coat concentration can be varied up to about 10% to complement the drug amount, and preferably about 3.1% to about 3.3%.
  • Film coating suspensions include combinations of one, two or three of the following components: carboxymethylcellulose sodium, carnauba wax, cellulose acetate phthalate, cetyl alcohol, confectioner's sugar, ethyl cellulose, gelatin, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, liquid glucose, maltodextrin, methyl cellulose, microcrystalline wax, Opadry and Opadry II, polymethacrylates, polyvinyl alcohol, shellac, sucrose, talc, titanium dioxide, and zein.
  • the preferred filler/disintegrant is microcrystalline cellulose.
  • the preferred superdisintegrant is croscarmellose sodium.
  • the preferred binder is hydroxypropyl cellulose.
  • a preferred surfactant is sodium lauryl sulfate.
  • the preferred diluent/compression aid is lactose hydrous spray dried.
  • the preferred lubricant is magnesium stearate.
  • the preferred solvent for formulating this compressed tablet is water.
  • the preferred film coating comprises: hydroxypropylcellulose, hydroxypropyl methylcellulose, and titanium dioxide.
  • the 300 mg film coated efavirenz tablet contains: Ingredient Amt per tablet Percent w/w Core Tablet: efavirenz 300 mg 50 microcrystalline cellulose NF 120 mg 20 hydroxypropyl cellulose LF NF 19.2 mg 3.2 croscarmellose sodium 30 mg 5 sodium lauryl sulfate 6 mg 1 lactose hydrous spray dried (EG) 118.8 mg 19.8 magnesium stearate (EG) 6 mg 1 Film Coating Material per Tablet: 3.1% by wt hydroxypropyl cellulose LF NF 8.05 mg 1.4 hydroxypropyl methylcellulose USP 6CPS 8.05 mg 1.4 titanium dioxide USP 3.1 mg 0.3 Tablet Weight: 619.2 mg
  • a process for the preparation of a 50% drug loaded compressed tablet comprising the following steps:
  • a process for the preparation of a 50% drug loaded compressed tablet comprising the following steps:
  • Wet granulation can be conducted using granulator mixers, such as a Fielder 10 L high shear granulator mixer, a drum or pan granulator, and a fluid bed granulator. Granulation can also be achieved by conducting dry granulation (without water) using a roller compaction process.
  • granulator mixers such as a Fielder 10 L high shear granulator mixer, a drum or pan granulator, and a fluid bed granulator.
  • Granulation can also be achieved by conducting dry granulation (without water) using a roller compaction process.
  • the drying step can be conducted using a Glatt WST-15 fluid bed drier or a tray drier.
  • the milling step can be conducted using mills such as a Comil or a Fitz mill.
  • the lubricating and blending steps can be conducted in a V-blender or a ribbon blender.
  • the compression step to form the tablet can be done a variety of presses including a beta press, single station F-press, the 6-station Korsh, etc.
  • Film coating can be performed in a Glatt Column coater, a smaller Hi-coater (9′′-12′′ pan), etc.
  • the formulation also is bioequivalent to a capsule with a smaller dose (200 mg), and more bioavailable than other tablet compositions.
  • the advantages over the capsule include robust processing and sorting steps, smaller size with a larger dose, and market preference.
  • the tablet composition also overcomes the expect loss of crystallinity of efavirenz by adding the lactose extra-granularly while maintaining the dissolution profile.
  • This formulation was determined to be bioequivalent to the capsule formulation being used in clinical trials.
  • the wet granulation process has been used to optimize the formulation such that about 80% dissolution of the drug occurs within 10 minutes in a 1% Sodium Dodecyl sulfate (SDS) solution, while stirring at a 50 rpm paddle speed.
  • SDS Sodium Dodecyl sulfate
  • Scheme 1 outlines the key steps in the synthesis of ( ⁇ )-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (efavirenz).
  • the chiral addition step allows for the enantioselective addition of the cyclopropylacetylide across the trifluoromethylketone of 1.
  • the p-methoxybenzyl (PMB)-protected amino alcohol, 2, produced is then deprotected to give the amino alcohol, 3.
  • the amino alcohol is then cyclized using a chloroformate and base to give efavirenz.
  • Scheme 2 outlines the preparation of efavirenz using an alternative process which is a chiral addition reaction.
  • the new chiral addition reaction allows for the elimination of the protection-deprotection sequence as outlined in Scheme 1.
  • Scheme 3 describes the process for the synthesis of the chiral intermediate used in the preparation of efavirenz. This reaction has been demonstrated to work using about 1.2 equivalents of cyclopropylacetylene and chiral additive, much lesss than the prior methods. The numerous chiral additives have been run and give high yields with a commerically available chiral ligand, such as N-methyl ephedrine and N-pyrrolidinyl norephedrine.
  • the organic layer is washed with water (1.5 L).
  • the combined aqueous layers are extracted with 2.5 L of toluene and saved for norephedrine recovery.
  • the toluene extract is combined with the organic solution and is concentrated to ⁇ 2.5 L.
  • Toluene is continuously feeded and distilled till THF is not detectable by GC.
  • the final volume is controlled at 3.9 L.
  • Heptane (5.2 L) is added over 1 h.
  • the slurry is cooled to 0° C., aged for 1 h, and filtered.
  • the solid is washed with heptane (2 cake volume) and dried to give 1.234 Kg (95.2% yield) of amino alcohol 3 as a white crystalline.
  • the material is 99.8 A % pure and 99.3% ee.
  • efavirenz starting material 400 g. is dissolved in 1.8 L of 2-propanol. The solution is filtered to remove extraneous matter. 1.95 L of deionized (DI) water is added to the solution over 30 to 60 minutes. 10 g. to 20 g. of efavirenz seed (Form II wetcake) is added to the solution. The seed bed is aged for 1 hour. The use of Intermig agitators is preferred to mix the slurry. If required (by the presence of extremely long crystals or a thick slurry), the slurry is wet-milled for 15-60 seconds. 2.25 L of DI water is added to the slurry over 4 to 6 hours.
  • DI deionized
  • the slurry is wet-milled for 15-60 seconds during the addition.
  • the slurry is aged for 2 to 16 hours until the product concentration in the supernatant remains constant.
  • the slurry is filtered to isolate a crystalline wet cake.
  • the wet cake is washed with 1 to 2 bed volumes of 30% 2-propanol in water and then twice with 1 bed volume of DI water each. The washed wet cake is dried under vacuum at 50° C.
  • efavirenz starting material 400 g. is dissolved in 1.8 L of 2-propanol.
  • a heel slurry is produced by mixing 20 g. of Form II efavirenz in 0.3 L of 30% (v/v) 2-propanol in water or retaining part of a slurry from a previous crystallization in the crystallizer.
  • the dissolved batch and 4.2 L of DI water are simultaneously charged to the heel slurry at constant rates over 6 hours to maintain a constant solvent composition in the crystallizer.
  • Use of Intermig agitators during the crystallization is preferred.
  • the slurry is wet-milled when the crystal lengths become excessively long or the slurry becomes too thick.
  • the slurry is aged for 2 to 16 hours until the product concentration in the supernatant remains constant.
  • the slurry is filtered to isolate a crystalline wet cake.
  • the wet cake is washed with 1 to 2 bed volumes of 30% 2-propanol in water and then twice with 1 bed volume of DI water each.
  • the washed wet cake is dried under vacuum at 50° C.
  • the solution was stirred at 0° C. for 1-2 h.
  • the solution of chloromagnesiumcyclopropylacetylide was then warmed to room temperature and was transferred into the zinc reagent via cannula over 5 min followed by vessel rinse with 0.36 L of THF.
  • the resulting mixture was aged at ⁇ 30° C. for 0.5 h and was then cooled to 20° C.
  • the ketoaniline 1 (1.00 kg, 4.47 mol) was added in one portion as a solid, and the resulting mixture was stirred at 20-28° C. for 3 h.
  • the salt was dissolved in a mixture of MTBE (6 L) and aq Na 2 CO 3 (1.18 kg in 6.25 L water). The layers were separated and the organic layer was washed with 1.25 L of water. The organic layer was then solvent switched into toluene.
  • the aqueous solution was basified to pH13 using 50% aq NaOH, and extracted with heptane (2 L).
  • the heptane solution was washed with water (1 L) and concentrated to remove residual IPAc and water. The final volume was adjusted to about 3 L.
  • the heptane solution was cooled to ⁇ 20° C., aged for 2 h, and filtered. The solid was washed with cold heptane (1 cake volume) and dried to give 1.269 kg solid (94% recovery).
  • Efavirenz 950 g was blended with microcrystalline cellulose (380 g) , sodium lauryl sulfate (19 g) , hydroxypropyl cellulose (60.8 g) and croscarmellose sodium (95 g) in a Fielder 10 L high shear granulator mixer for four minutes. At least about 1.1 weight % water per weight of efavirenz (1.045 L) was added to wet granulate the blended mixture over about 6 minutes to about 8 minutes to agglomerate the mixture using an appropriate spray nozzle. The granulated mixture is dried to a moisture content of about 2% to about 5% in a Glatt WST-15 fluid bed drier.
  • the dried mixture was milled using a 40 G round screen in a Comil.
  • the milled mixture was blended in a V-Blender with lactose for 4 minutes (calculated amount is the amount needed to make the final composition contain 19.8% lactose by weight).
  • the blended mixture was lubricated with magnesium stearate (calculated amount is the amount needed to make the final composition contain 1% magnesium stearate by weight) in the V-Blender for 3 minutes.
  • the lubricated mixture was compressed using a beta press to give a compressed tablet of the desired shape.
  • the compressed tablets were film coated with an aqueous coating suspension that contains 2.5% hydroxypropyl cellulose (HPC); 2.5% hydroxymethylcellulose (HPMC); and 1% titanium dioxide (TiO 2 ) and 94% water by weight percent in a 19′′ O'Hara pan coater to a coat weight of about 3.3% per tablet. Note that the coat is the dried form of the suspension.
  • HPC hydroxypropyl cellulose
  • HPMC 2.5% hydroxymethylcellulose
  • TiO 2 titanium dioxide
  • the coat is the dried form of the suspension.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to a 50% drug loaded compressed tablet formulation for efavirenz. Efavirenz is a non-nucleoside reverse trancriptase inhibitor being studied clinically for use in the treatment of HIV infections and AIDS.

Description

    BACKGROUND OF THE INVENTION
  • This invention relates to a compressed tablet formulation for efavirenz, which is 50 percent by weight drug loaded and can optionally be film coated. Efavirenz is a non-nucleoside reverse trancriptase inhibitor being studied clinically for use in the treatment of HIV infections and AIDS. A process for the manufacture of the compressed tablet is also disclosed. [0001]
  • The synthesis of efavirenz and structurally similar reverse transcriptase inhibitors are disclosed in U.S. Pat. Nos. 5,519,021, 5,663,169, 5,665,720 and the corresponding PCT International Patent Application WO 95/20389, which published on Aug. 3, 1995. Additionally, the asymmetric synthesis of an enantiomeric benzoxazinone by a highly enantioselective acetylide addition and cyclization sequence has been described by Thompson, et al., Tetrahedron Letters 1995, 36, 8937-8940, as well as the PCT publication, WO 96/37457, which published on Nov. 28, 1996. [0002]
  • Additionally, several applications have been filed which disclose various aspects of the synthesis of(−)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one including: 1) a process for making the chiral alcohol, U.S. Ser. No. 60/035,462, filed Jan. 14, 1997; 2) the chiral additive, U.S. Ser. No. 60/034,926, filed Jan. 10, 1997; 3) the cyclization reaction, U.S. Ser. No. 60/037,059, filed Feb. 12, 1997; and the anti-solvent crystallization procedure, U.S. Ser. No. 60/037,385 filed Feb. 5, 1997 and U.S. Ser. No. 60/042,807 filed Apr. 8, 1997. [0003]
  • The compressed tablet is an improved formulation which allows one to utilize a tablet over a capsule. The compressed tablet has been demonstrated to have comparable bioavailability data to that seen with the capsule. The key feature of the formulation is the use of a superdisintegrant and disintegrant intragranularly to achieved a bioequivalent formulation. The compressed tablet form was difficult to manage as efavirenz is fragile and the drug loses crystallinity upon compression. This was overcome by adding lactose extragranularly. [0004]
    • SUMMARY OF THE INVENTION
  • The instant invention relates to a compressed tablet of efavirenz which is a 50 percent drug loaded formulation. [0005]
  • The instant invention also relates to the process for manufacture of the compressed tablet using a wet granulation method. [0006]
    • DETAILED DESCRIPTION OF THE INVENTION
  • The instant invention relates to a compressed tablet of efavirenz formulation which is 50 percent by weight drug loaded and can optionally be film coated. [0007]
  • The compressed tablet comprises: efavirenz, filler/disintegrant, superdisintegrant, binder, surfactant, filler/compression aid, lubricant, and solvent, wherein of efavirenz is about 50% by weight of the total composition of the compressed tablet. [0008]
  • The efavirenz concentration can be varied from about 1 to about 75 % by changing the concentration of remaining excipients. Furthermore, changing the tooling can give a wide ranges of doses, e.g. a 20 mg dose in a 40 mg tablet, a 300 mg dose in a 600 mg tablet, or a 600 mg dose in a 1200 mg compressed tablet, with the same composition. Removing the lactose from the formulation gives about 70% drug in the formulation giving a 600 mg dose in a 860 mg compressed tablet. These variations are very straightforward to effect. This formulation will allow one to formulate efavirenz as a single 600 mg dose as an 860 mg compressed tablet, where as a capsule formulation requires the administration of at least two capsules to dose with 600 mg of efavirenz. [0009]
  • The invention contemplates the use of any pharmaceutically acceptable fillers/compression aids, disintegrants, super-disintegrants, lubricants, binders, surfactants, film coatings, and solvents. Examples of these components are set forth below and are described in more detail in the Handbook of Pharmaceutical Excipients, Second Edition, Ed. A. Wade and P. J. Weller, 1994, The Pharmaceutical Press, London, England. [0010]
  • Fillers and compression aid concentrations can be varied between about 5% to about 80% to complement the drug amount. Examples of fillers/compression aids include: lactose, calcium carbonate, calcium sulfate, compressible sugars, dextrates, dextrin, dextrose, calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin mannitol, powdered cellulose, pregelatinized starch, and sucrose. [0011]
  • Examples of disintegrants include: alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, colloidal silicon dioxide, croscarmellose sodium, crospovidone, guar gum, magnesium aluminum silicate, methylcellulose, microcrystalline cellulose, polyacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate and starch. [0012]
  • Examples of fillers (also referred to as a diluent) include: calcium carbonate, calcium sulfate, compressible sugars, confectioner's sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, glyceryl palmitostearate, hydrogenated vegetable oil (type I), kaolin, lactose, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates, potassium chloride, powdered cellulose, pregelatinized starch, sodium chloride, sorbitol, starch, sucrose, sugar spheres, talc and tribasic calcium phosphate. [0013]
  • Superdisintegrant concentration can be varied between about 1% to about 20% to complement the drug amount and obtain reasonable dissolution. Examples of super-disintegrants include the disintegrants listed above, carboxymethylcellulose sodium, croscarmellose sodium, povidone, guar gum, polacrilin potassium, and pregelatinized starch. [0014]
  • Binder concentration can be varied between 1 and 10% to complement the drug amount. Examples of binders include: acacia, alginic acid, carbomer, carboxymethylcellulose sodium, dextrin, ethylcellulose, gelatin, guar gum, hydrogenated vegetable oil (type I), hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, liquid glucose, magnesium aluminaum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone, pregelatinized starch, sodium alginate, starch, and zein. [0015]
  • Examples of surfactants comprises anionic and cationic surfactants, such as sodium lauryl sulfate, docusate sodium (dioctyl sulfosuccinate sodium salt), benzalkonium chloride, benzethonium chloride, and cetrimide (alkyltrimethylammonium bromide, predominantly C[0016] 14 alkyl).
  • Examples of lubricants include: calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, light mineral oil, magnesium stearate, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc and zinc stearate. [0017]
  • Examples of solvent comprises: water, ethanol or mixtures thereof. [0018]
  • The compressed tablet can also be film coated. Film coat concentration can be varied up to about 10% to complement the drug amount, and preferably about 3.1% to about 3.3%. Film coating suspensions include combinations of one, two or three of the following components: carboxymethylcellulose sodium, carnauba wax, cellulose acetate phthalate, cetyl alcohol, confectioner's sugar, ethyl cellulose, gelatin, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, liquid glucose, maltodextrin, methyl cellulose, microcrystalline wax, Opadry and Opadry II, polymethacrylates, polyvinyl alcohol, shellac, sucrose, talc, titanium dioxide, and zein. [0019]
  • The preferred filler/disintegrant is microcrystalline cellulose. The preferred superdisintegrant is croscarmellose sodium. The preferred binder is hydroxypropyl cellulose. A preferred surfactant is sodium lauryl sulfate. The preferred diluent/compression aid is lactose hydrous spray dried. The preferred lubricant is magnesium stearate. The preferred solvent for formulating this compressed tablet is water. The preferred film coating comprises: hydroxypropylcellulose, hydroxypropyl methylcellulose, and titanium dioxide. [0020]
  • The 300 mg film coated efavirenz tablet contains: [0021]
    Ingredient Amt per tablet Percent w/w
    Core Tablet:
    efavirenz 300 mg 50
    microcrystalline cellulose NF 120 mg 20
    hydroxypropyl cellulose LF NF 19.2 mg 3.2
    croscarmellose sodium 30 mg 5
    sodium lauryl sulfate 6 mg 1
    lactose hydrous spray dried (EG) 118.8 mg 19.8
    magnesium stearate (EG) 6 mg 1
    Film Coating Material per Tablet: 3.1% by wt
    hydroxypropyl cellulose LF NF 8.05 mg 1.4
    hydroxypropyl methylcellulose USP 6CPS 8.05 mg 1.4
    titanium dioxide USP 3.1 mg 0.3
    Tablet Weight: 619.2 mg
  • A process for the preparation of a 50% drug loaded compressed tablet comprising the following steps: [0022]
  • (a) blending efavirenz with a filler/disintegrant, super-disintegrant, binder and surfactant; [0023]
  • (b) adding at least 1.1% by weight of water per weight of efavirenz to wet granulate the blended mixture to agglomerate the mixture; [0024]
  • (c) drying the granulated mixture to a moisture content of about 0% to about 10%; [0025]
  • (d) milling the dried mixture to granulate to a uniform size; [0026]
  • (e) blending the milled mixture with a filler/compression aid; [0027]
  • (f) lubricating the blended mixture with a lubricant; and [0028]
  • (g) compressing the lubricated mixture to a compressed tablet of the desired shape. [0029]
  • The process as recited above which comprises the additional step of film coating the compressed tablet with a film coating suspension to produce the desired film coated compressed tablet. [0030]
  • The process as recited above wherein the granulated mixture is dried to a moisture contant of about 2% to about 5%. [0031]
  • A process for the preparation of a 50% drug loaded compressed tablet comprising the following steps: [0032]
  • (a) blending efavirenz with microcrystalline cellulose, sodium lauryl sulfate, hydroxypropyl cellulose and croscarmellose sodium; [0033]
  • (b) adding at least 1.1 weight % water per weight of efavirenz to wet granulate the blended mixture for about 3 minutes to about 8 minutes to agglomerate the mixture; [0034]
  • (c) drying the granulated mixture to a moisture content of about 2% to about 5%; [0035]
  • (d) milling the dried mixture to a granulate of about 250μ to about 75μ; [0036]
  • (e) blending the milled mixture with lactose; [0037]
  • (f) lubricating the blended mixture with magnesium stearate; [0038]
  • (g) compressing the lubricated mixture to a compressed tablet of the desired shape; and [0039]
  • (h) film coating the compressed tablet with a film coating suspension to about 3.1% to about 3.3% of weight of compressed tablet. [0040]
  • The process as recited above wherein the blended mixture is wet granulated for about 6 minutes. [0041]
  • The process as recited above wherein the film coating suspension comprising hydroxypropylcellulose, hydroxypropyl methylcellulose, and titanium dioxide. [0042]
  • Wet granulation can be conducted using granulator mixers, such as a Fielder 10 L high shear granulator mixer, a drum or pan granulator, and a fluid bed granulator. Granulation can also be achieved by conducting dry granulation (without water) using a roller compaction process. [0043]
  • The drying step can be conducted using a Glatt WST-15 fluid bed drier or a tray drier. [0044]
  • The milling step can be conducted using mills such as a Comil or a Fitz mill. [0045]
  • The lubricating and blending steps can be conducted in a V-blender or a ribbon blender. [0046]
  • The compression step to form the tablet can be done a variety of presses including a beta press, single station F-press, the 6-station Korsh, etc. [0047]
  • Film coating can be performed in a Glatt Column coater, a smaller Hi-coater (9″-12″ pan), etc. [0048]
  • The formulation also is bioequivalent to a capsule with a smaller dose (200 mg), and more bioavailable than other tablet compositions. The advantages over the capsule include robust processing and sorting steps, smaller size with a larger dose, and market preference. The tablet composition also overcomes the expect loss of crystallinity of efavirenz by adding the lactose extra-granularly while maintaining the dissolution profile. [0049]
  • The increased drug loading often compromises the dissolution profile of the drug. This hurdle was overcome by including the super-disintegrant intragranularly, as well as the disintegrant intragranularly. The lactose was added extra-ganularly to maintain the crystallinity of efavirenz. [0050]
  • This formulation was determined to be bioequivalent to the capsule formulation being used in clinical trials. The wet granulation process has been used to optimize the formulation such that about 80% dissolution of the drug occurs within 10 minutes in a 1% Sodium Dodecyl sulfate (SDS) solution, while stirring at a 50 rpm paddle speed. [0051]
  • Preparation of (−)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (currently referred to by its generic name efavirenz or code name DMP-266). [0052]
  • Scheme 1 outlines the key steps in the synthesis of (−)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (efavirenz). The chiral addition step allows for the enantioselective addition of the cyclopropylacetylide across the trifluoromethylketone of 1. The p-methoxybenzyl (PMB)-protected amino alcohol, 2, produced is then deprotected to give the amino alcohol, 3. The amino alcohol is then cyclized using a chloroformate and base to give efavirenz. [0053]
    Figure US20010014352A1-20010816-C00001
  • Scheme 2 outlines the preparation of efavirenz using an alternative process which is a chiral addition reaction. The new chiral addition reaction allows for the elimination of the protection-deprotection sequence as outlined in Scheme 1. [0054]
    Figure US20010014352A1-20010816-C00002
  • Scheme 3 describes the process for the synthesis of the chiral intermediate used in the preparation of efavirenz. This reaction has been demonstrated to work using about 1.2 equivalents of cyclopropylacetylene and chiral additive, much lesss than the prior methods. The numerous chiral additives have been run and give high yields with a commerically available chiral ligand, such as N-methyl ephedrine and N-pyrrolidinyl norephedrine. [0055]
    Figure US20010014352A1-20010816-C00003
  • The cyclization of the amino alcohol, 3 to produce the 1,4-dihydro-2H-3,1-benzoxazin-2-one, 4 is outlined in Scheme 4 below. The reaction can be carried out as a one-step process, or alternatively a two step process with the potential isolation of the intermediate carbamate, 5 depending upon the chloroformate utilized. It has been demonstrated that the aryl chloroformates form less stable carbamates such that when they are treated with aqueous base they cyclize to the product, in a one-step process. The alkyl chloroformate, alternatively, provides an alkyl carbamate, a key intermediate capable of being isolated and purified prior to carrying out the cyclization step. Based upon the stability of the alkyl carbamates, a viable two step process for the preparation of efavirenz has been developed which comprises the formation of the alkyl carbamate intermediate, 5 followed by the cyclization of the carbamate to give the desired product, 4. Additionally, it has been demonstrate that phosgene can also be used. [0056]
    Figure US20010014352A1-20010816-C00004
  • The compressed tablet is formulated following the sequence of steps outlined in Scheme 5. [0057]
    Figure US20010014352A1-20010816-C00005
  • The following examples are meant to be illustrative of the present invention. These examples are presented to exemplify the invention and are not to be construed as limiting the scope of the invention. [0058]
    • EXAMPLE 1
  • [0059]
    Figure US20010014352A1-20010816-C00006
    Materials Amount Mol MW
    Ketone 1a 1.00 kg g 4.47 223.58
    (1R, 2S)-N-pyrrolidinyl norephedrine 1.35 kg 6.58 205.30
    cyclopropyl acetylene 361.9 g 5.47 66.10
    n-BuMgCl (2.0 M in THF) 2.68 L 5.37
    2,2,2-trifluoroethanol (99%) 429.5 g 4.29 100.04
    ZnEt2 (0.892 M in hexane) 6.02 L 5.37
    THF 9.36 L
    30% K2CO3 550 mL
    30% citric acid 2.0 L
    Toluene (for crystallization, 2 mL/g of 4) 2.6 L
    Heptane (for crystallization, 4 mL/g of 4) 5.2 L
  • To a solution of trifluoroethanol and (1R, 2S)-N-pyrrolidinyl norephedrine in THF (9 L) under nitrogen is added a solution of diethylzinc in hexane at 0° C. slowly enough to keep the temperature below 30° C. The mixture is stirred at room temperature for 0.5˜1 h. In another dry flask a solution of chloromagnesium cyclopropyl acetylide is prepared as follows: To neat cyclopropyl acetylene at 0° C. is added a solution of n-butylmagnesium chloride slowly enough to keep the internal temperature ≦30° C. The solution is stirred at 0° C. for ˜40 min and transfered to the zinc reagent via cannula with 0.36 L of THF as a wash. The mixture is cooled to −10° C. and ketoaniline 1[0060] a is added. The mixture is stirred at −2 to −8° C. for 35 h, warmed to room temperature, stirred for 3 h, and quenched with 30% potassium carbonate over 1.5 h. The mixture is stirred for 4 h and the solid is removed by filtration and washed with THF (2 cake volume). The wet solid still contains ˜18 wt % of pyrrolidinyl norephedrine and is saved for further study. The filtrate and wash are combined and treated with 30% citric acid. The two layers are separated. The organic layer is washed with water (1.5 L). The combined aqueous layers are extracted with 2.5 L of toluene and saved for norephedrine recovery. The toluene extract is combined with the organic solution and is concentrated to ˜2.5 L. Toluene is continuously feeded and distilled till THF is not detectable by GC. The final volume is controlled at 3.9 L. Heptane (5.2 L) is added over 1 h. The slurry is cooled to 0° C., aged for 1 h, and filtered. The solid is washed with heptane (2 cake volume) and dried to give 1.234 Kg (95.2% yield) of amino alcohol 3 as a white crystalline. The material is 99.8 A % pure and 99.3% ee.
    • EXAMPLE 2
  • [0061]
    Figure US20010014352A1-20010816-C00007
    FW g mL mmol equiv
    amino alcohol 3 289 100 346 1
    4-nitrophenylchloroformate 201.6 73.2 363 1.05
    KHCO3 100 45 450 1.3
    2N KOH 56 346 692 2.0
    H2O 654
    MTBE 500
  • To a three necked round bottom flask, equipped with a mechanical stirrer, nitrogen line, and thermocouple, was charged the solid amino alcohol 3, MTBE (500 mL), and aqueous KHCO[0062] 3 (45 g in 654 mL H2O). Solid 4-nitrophenyl chloroformate was added, in 4 batches, at 25° C. During the addition the solution pH was monitored. The pH was maintained between 8.5 and 4 during the reaction and ended up at 8.0. The mixture was stirred at 20-25° C. for two hours. Aqueous KOH (2N) was added over 20 minutes, until the pH of the aqueous layer reached 11.0.
  • The layers were separated and 500 mL brine was added to the MTBE layer. 0.1 N Acetic acid was added until the pH was 6-7. The layers were separated and the organic phase was washed with brine (500 mL). At this point the mixture was solvent switched to EtOH/IPA and crystallized as recited in Examples 5 and 6. [0063]
    • EXAMPLE 3
  • [0064]
    Figure US20010014352A1-20010816-C00008
    FW g mL mmol equiv
    amino alcohol 3a 289 100 346 1
    phosgene (20 wt % in toluene) 99 41 216 415 1.2
    KHCO3 100 86.5 865 2.5
    H2O 500
    Toluene 500
  • To a three necked round bottom flask, equipped with a mechanical stirrer, nitrogen line, and thermocouple, was charged the solid amino alcohol 3[0065] a, toulene (500 mL), and aqueous KHCO3 (86.5 g in 500 mL H2O). Phosgene solution in toulene was added at 25° C., and the mixture was stirred at 20-25° C. for two hours.
  • The layers were separated and the organic phase was washed with brine (500 mL). At this point the mixture was solvent switched to EtOH/IPA and crystallized as recited in Examples 5 and 6. [0066]
    • EXAMPLE 4
  • [0067]
    Figure US20010014352A1-20010816-C00009
    FW g mL mmol equiv
    amino alcohol 3a 289 100 346 1
    phosgene (gas) 99
    KHCO3 100 86.5 865 2.5
    H2O 500
    MTBE 500
  • To a three necked round bottom flask, equipped with a mechanical stirrer, nitrogen line, and thermocouple, was charged the solid amino alcohol 3[0068] a, MTBE (500 mL), and aqueous KHCO3 (86.5 g in 500 mL H2O). Phosgene gas was slowly passed into the solution at 25° C., until the reaction was complete.
  • The layers were separated and the organic phase was washed with brine (500 mL). At this point the mixture was solvent switched to EtOH/IPA and crystallized as recited in Examples 5 and 6. [0069]
    • EXAMPLE 5
  • Crystallization of efavirenz from 30% 2-Propanol in Water using a ratio of 15 ml solvent per gram efavirenz Using Controlled Anti-Solvent Addition on a 400 g Scale. [0070]
  • 400 g. of efavirenz starting material is dissolved in 1.8 L of 2-propanol. The solution is filtered to remove extraneous matter. 1.95 L of deionized (DI) water is added to the solution over 30 to 60 minutes. 10 g. to 20 g. of efavirenz seed (Form II wetcake) is added to the solution. The seed bed is aged for 1 hour. The use of Intermig agitators is preferred to mix the slurry. If required (by the presence of extremely long crystals or a thick slurry), the slurry is wet-milled for 15-60 seconds. 2.25 L of DI water is added to the slurry over 4 to 6 hours. If required (by the presence of extremely long crystals or a thick slurry), the slurry is wet-milled for 15-60 seconds during the addition. The slurry is aged for 2 to 16 hours until the product concentration in the supernatant remains constant. The slurry is filtered to isolate a crystalline wet cake. The wet cake is washed with 1 to 2 bed volumes of 30% 2-propanol in water and then twice with 1 bed volume of DI water each. The washed wet cake is dried under vacuum at 50° C. [0071]
    • EXAMPLE 6
  • Crystallization of efavirenz from 30% 2-Propanol in Water using a ratio of 15 ml solvent per gram efavirenz Using a Semi-Continuous Process on a 400 g Scale. [0072]
  • 400 g. of efavirenz starting material is dissolved in 1.8 L of 2-propanol. A heel slurry is produced by mixing 20 g. of Form II efavirenz in 0.3 L of 30% (v/v) 2-propanol in water or retaining part of a slurry from a previous crystallization in the crystallizer. The dissolved batch and 4.2 L of DI water are simultaneously charged to the heel slurry at constant rates over 6 hours to maintain a constant solvent composition in the crystallizer. Use of Intermig agitators during the crystallization is preferred. During this addition the slurry is wet-milled when the crystal lengths become excessively long or the slurry becomes too thick. The slurry is aged for 2 to 16 hours until the product concentration in the supernatant remains constant. The slurry is filtered to isolate a crystalline wet cake. The wet cake is washed with 1 to 2 bed volumes of 30% 2-propanol in water and then twice with 1 bed volume of DI water each. The washed wet cake is dried under vacuum at 50° C. [0073]
    • EXAMPLE 7
  • Preparation of Amino Alcohol 3 and ee Upgrading—Through Process [0074]
    Figure US20010014352A1-20010816-C00010
    Materials Amount Mol MW
    Ketone 1 1.00 kg 4.47 223.58
    (1R, 2S)-N-Pyrrolidinyl norephedrine 1.35 kg 6.58 205.30
    Cyclopropyl acetylene 361.9 g 5.47 66.10
    n-BuMgCl (2.0 M in THF) 2.68 L 5.37
    Trifluoroethanol (99%) 429.5 g 4.29 100.04
    ZnEt2 (0.892 M in hexane) 6.02 L 5.37
    THF 9.36 L
    30% K2CO3 1.2 L
    1 M Citric acid 3.5 L
    Heptane 12 L
    Isopropyl acetate (IPAc) 40 L
    12N HCl 405 mL 4.88
    tert-Butyl methyl ether (MTBE) 6 L
    Toluene 6.25 L
    Na2CO3 1.2 kg 11.25
  • A solution of diethyl zinc in hexane was added to a solution of trifluoroethanol (429.5 g, 4.29 mol) and (1R, 2S)-N-pyrrolidinyl norephedrine (1.35 kg, 6.58 mol) in THF (9 L), under nitrogen, at 0° C. The resulting mixture was stirred at room temperature for approx. 30 min. In another dry flask a solution of chloromagnesiumcyclopropylacetylide was prepared as follows. To a solution of n-butylmagnesium chloride in THF (2 M, 2.68 L, 5.37 mol) was added neat cyclopropylacetylene at 0° C. keeping the temperature ≦25° C. The solution was stirred at 0° C. for 1-2 h. The solution of chloromagnesiumcyclopropylacetylide was then warmed to room temperature and was transferred into the zinc reagent via cannula over 5 min followed by vessel rinse with 0.36 L of THF. The resulting mixture was aged at ˜30° C. for 0.5 h and was then cooled to 20° C. The ketoaniline 1 (1.00 kg, 4.47 mol) was added in one portion as a solid, and the resulting mixture was stirred at 20-28° C. for 3 h. [0075]
  • The reaction was quenched with 30% aq. potassium carbonate (1.2 L) and aged for 1 h. The solid waste was filtered and the cake was washed with THF (3 cake volumes). The filtrate and wash were combined and solvent switched to IPAc. [0076]
  • The IPAc solution of product 3 and pyrrolidinyl norephedrine was washed with citric acid (3.5 L) and with water (1.5 L). The combined aqueous layers were extracted with IPAc (2 L) and saved for norephedrine recovery. To the combined organic layers was added 12N HCl (405 mL, 4.88 mol), to form a thin slurry of the amino alcohol-HCl salt. The mixture was aged for 30 min at 25° C. and was then dried azeotropically. [0077]
  • The slurry was aged at 25° C. for 30 min and filtered. The cake was washed with 2.5 L of IPAc and dried at 25° C. under vacuum/nitrogen for 24 h to give 1.76 kg of the wet HCl salt. [0078]
  • The salt was dissolved in a mixture of MTBE (6 L) and aq Na[0079] 2CO3 (1.18 kg in 6.25 L water). The layers were separated and the organic layer was washed with 1.25 L of water. The organic layer was then solvent switched into toluene.
  • Heptane (5 L) was added over 1 h at 25° C. The slurry was cooled to 0° C., aged for 1 h, and filtered. The solid was washed with heptane (2 cake volumes) and was dried to give 1.166 kg (90% overall yield) of amino alcohol 3 as a white crystalline solid. Norephedrine recovery [0080]
  • The aqueous solution was basified to pH13 using 50% aq NaOH, and extracted with heptane (2 L). The heptane solution was washed with water (1 L) and concentrated to remove residual IPAc and water. The final volume was adjusted to about 3 L. The heptane solution was cooled to −20° C., aged for 2 h, and filtered. The solid was washed with cold heptane (1 cake volume) and dried to give 1.269 kg solid (94% recovery). [0081]
    • EXAMPLE 8
  • [0082]
    50% Drug-Loaded Compressed tablet Of Efavirenz
    Ingredient Amt per batch
    Core Tablet:
    efavirenz 950 g
    microcrystalline cellulose NF 380 g
    hydroxypropyl cellulose LF NF 60.8 g
    croscarmellose sodium 95 g
    sodium lauryl sulfate 19 g
    lactose hydrous spray dried (EG)* 19.8% w/w
    magnesium stearate (EG)* 1% w/w
    water 1.045 L
    Film Coating Material per Tablet: 3.3% by wt of tablet
    hydroxypropyl cellulose LF NF 8.54 mg (2.5%)
    hydroxypropyl methylcellulose USP 6CPS 8.54 mg (2.5%)
    titanium dioxide USP 3.42 mg (1%)
    water (94 %)
  • Efavirenz (950 g) was blended with microcrystalline cellulose (380 g) , sodium lauryl sulfate (19 g) , hydroxypropyl cellulose (60.8 g) and croscarmellose sodium (95 g) in a Fielder 10 L high shear granulator mixer for four minutes. At least about 1.1 weight % water per weight of efavirenz (1.045 L) was added to wet granulate the blended mixture over about 6 minutes to about 8 minutes to agglomerate the mixture using an appropriate spray nozzle. The granulated mixture is dried to a moisture content of about 2% to about 5% in a Glatt WST-15 fluid bed drier. The dried mixture was milled using a 40 G round screen in a Comil. The milled mixture was blended in a V-Blender with lactose for 4 minutes (calculated amount is the amount needed to make the final composition contain 19.8% lactose by weight). The blended mixture was lubricated with magnesium stearate (calculated amount is the amount needed to make the final composition contain 1% magnesium stearate by weight) in the V-Blender for 3 minutes. The lubricated mixture was compressed using a beta press to give a compressed tablet of the desired shape. The compressed tablets were film coated with an aqueous coating suspension that contains 2.5% hydroxypropyl cellulose (HPC); 2.5% hydroxymethylcellulose (HPMC); and 1% titanium dioxide (TiO[0083] 2) and 94% water by weight percent in a 19″ O'Hara pan coater to a coat weight of about 3.3% per tablet. Note that the coat is the dried form of the suspension.

Claims (23)

What is claimed is:
1. A compressed tablet comprising: efavirenz, filler/disintegrant, superdisintegrant, binder, surfactant, diluent/compression aid, lubricant, and solvent, wherein efavirenz is about 50% by weight of the total composition of the compressed tablet.
2. The compressed tablet, as recited in
claim 1
, wherein the filler comprises: lactose, calcium carbonate, calcium sulfate, compressible sugars, dextrates, dextrin, dextrose, calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin mannitol, powdered cellulose, pregelatinized starch, and sucrose.
3. The compressed tablet, as recited in
claim 2
, wherein the disintegrant and superdisintegrant comprise: alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, colloidal silicon dioxide, croscarmellose sodium, crospovidone, guar gum, magnesium aluminum silicate, methylcellulose, microcrystalline cellulose, polyacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate and starch.
4. The compressed tablet, as recited in
claim 3
, wherein the binder comprises: acacia, alginic acid, carbomer, dextrin, ethylcellulose, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone, pregelatinized starch, sodium alginate, starch, and zein.
5. The compressed tablet, as recited in
claim 4
, wherein the surfactant comprises: sodium lauryl sulfate, docusate sodium, benzalkonium chloride, benzethonium chloride, and cetrimide.
6. The compressed tablet, as recited in
claim 5
, wherein the filler/compression aid comprises: calcium carbonate, calcium sulfate, compressible sugars, confectioner's sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, glyceryl palmitostearate, hydrogenated vegetable oil (type I), kaolin, lactose, such as lactose hydrous spray dried, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates, potassium chloride, powdered cellulose, pregelatinized starch, sodium chloride, sorbitol, starch, sucrose, sugar spheres, talc and tribasic calcium phosphate.
7. The compressed tablet, as recited in
claim 6
, wherein the lubricant comprises: calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, light mineral oil, magnesium stearate, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc and zinc stearate.
8. The compressed tablet, as recited in
claim 7
, wherein the solvent comprises: water, ethanol or mixtures thereof.
9. The compressed tablet, as recited in
claim 8
, wherein the filler/disintegrant is a microcrystalline cellulose.
10. The compressed tablet, as recited in
claim 9
, wherein the superdisintegrant is a croscarmellose sodium.
11. The compressed tablet, as recited in
claim 10
, wherein the binder is a hydroxypropyl cellulose.
12. The compressed tablet, as recited in
claim 11
, wherein the surfactant is a sodium lauryl sulfate.
13. The compressed tablet, as recited in
claim 12
, wherein the filler/compression aid is a lactose hydrous spray dried.
14. The compressed tablet, as recited in
claim 13
, wherein the lubricant is a magnesium stearate.
15. The compressed tablet, as recited in
claim 14
, comprising efavirenz, microcrystalline cellulose NF, hydroxypropyl cellulose LF NF, croscarmellose sodium, sodium lauryl sulfate, lactose hydrous spray dried (EG), and magnesium stearate (EG).
16. The compressed tablet, as recited in
claim 15
, containing about 300 mg of efavirenz, about 120 mg microcrystalline cellulose NF, about 19.2 mg hydroxypropyl cellulose LF NF, about 30 mg croscarmellose sodium, about 6 mg sodium lauryl sulfate, about 118.8 mg lactose hydrous spray dried (EG), and about 6 mg magnesium stearate (EG).
17. A process for the preparation of a 50% drug loaded compressed tablet comprising the following steps:
(a) blending efavirenz with a filler/disintegrant, super-disintegrant, binder and surfactant;
(b) adding at least 1.1% by weight of water per weight of efavirenz to wet granulate the blended mixture to agglomerate the mixture;
(c) drying the granulated mixture to a moisture content of about 0% to about 10%;
(d) milling the dried mixture to granulate to a uniform size;
(e) blending the milled mixture with a filler/compression aid;
(f) lubricating the blended mixture with a lubricant; and
(g) compressing the lubricated mixture to a compressed tablet of the desired shape.
18. The process as recited in
claim 19
 which comprises the additional step of film coating the compressed tablet with a film coating suspension to produce the desired film coated compressed tablet.
19. The process as recited in
claim 18
 wherein the granulated mixture is dried to a moisture content of about 2% to about 5%.
20. A process for the preparation of a 50% drug loaded film coated compressed tablet comprising the following steps:
(a) blending efavirenz with microcrystalline cellulose, sodium lauryl sulfate, hydroxypropyl cellulose and croscarmellose sodium;
(b) adding at least 1.1 weight % water per weight of efavirenz to wet granulate the blended mixture for about 3 minutes to about 8 minutes to agglomerate the mixture;
(c) drying the granulated mixture to a moisture content of about 2% to about 5%;
(d) milling the dried mixture to a granulate of about 250μ to about 75μ;
(e) blending the milled mixture with lactose;
(f) lubricating the blended mixture with magnesium stearate;
(g) compressing the lubricated mixture to a compressed tablet of the desired shape; and
(h) film coating the compressed tablet with a film coating suspension to about 1% to about 10% by weight of the weight of compressed tablet.
21. The process as recited
claim 20
, wherein the blended mixture is wet granulated for about 6 minutes.
22. The process as recited
claim 21
, wherein the film coating suspension comprising hydroxypropylcellulose, hydroxypropyl methylcellulose, and titanium dioxide.
23. The process as recited
claim 22
, wherein the compressed tablet is film coated with the film coating suspension to about 3.1% to about 3.3% by weight of the weight of compressed tablet.
US09/312,617 1998-05-27 1999-05-17 Compressed tablet formulation Abandoned US20010014352A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/312,617 US20010014352A1 (en) 1998-05-27 1999-05-17 Compressed tablet formulation
US09/894,921 US7060294B2 (en) 1998-05-27 2001-06-28 Compressed tablet formulation
US11/404,357 US7595063B2 (en) 1998-05-27 2006-04-14 Compressed tablet formulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8692198P 1998-05-27 1998-05-27
US09/312,617 US20010014352A1 (en) 1998-05-27 1999-05-17 Compressed tablet formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/894,921 Continuation US7060294B2 (en) 1998-05-27 2001-06-28 Compressed tablet formulation

Publications (1)

Publication Number Publication Date
US20010014352A1 true US20010014352A1 (en) 2001-08-16

Family

ID=26775309

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/312,617 Abandoned US20010014352A1 (en) 1998-05-27 1999-05-17 Compressed tablet formulation
US09/894,921 Expired - Lifetime US7060294B2 (en) 1998-05-27 2001-06-28 Compressed tablet formulation
US11/404,357 Expired - Fee Related US7595063B2 (en) 1998-05-27 2006-04-14 Compressed tablet formulation

Family Applications After (2)

Application Number Title Priority Date Filing Date
US09/894,921 Expired - Lifetime US7060294B2 (en) 1998-05-27 2001-06-28 Compressed tablet formulation
US11/404,357 Expired - Fee Related US7595063B2 (en) 1998-05-27 2006-04-14 Compressed tablet formulation

Country Status (1)

Country Link
US (3) US20010014352A1 (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090720A1 (en) 2002-04-23 2003-11-06 Novartis Ag High drug load tablet
US20050079135A1 (en) * 2003-08-26 2005-04-14 Haslam Robert Paul Pharmaceutical formulation comprising lanthanum compounds
US20050239679A1 (en) * 2002-10-18 2005-10-27 Solvay Interox Gmbh Method for producing dust-free alkaline earth peroxides
US20060121127A1 (en) * 2003-08-26 2006-06-08 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
US20060153932A1 (en) * 2004-07-27 2006-07-13 Shire Pharmaceuticals, Inc. Method of treating hyperphosphataemia using lanthanum hydroxycarbonate
US20070077295A1 (en) * 2005-06-13 2007-04-05 Gilead Sciences, Inc. Method and composition for pharmaceutical product
US20070099902A1 (en) * 2005-06-13 2007-05-03 Bristol-Myers Squibb & Gilead Sciences, Llc Unitary pharmaceutical dosage form
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
US20070116782A1 (en) * 2001-04-23 2007-05-24 Shire International Licensing B.V. Use of rare earth compounds for the prevention of kidney stone disease
US20070259052A1 (en) * 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
US20080268034A1 (en) * 2005-01-07 2008-10-30 Girish Karanth Solid Oral Dosage Forms of Ziprasidone Containing Colloidal Silicone Dioxide
US20090036408A1 (en) * 2003-01-14 2009-02-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US20100015246A1 (en) * 2000-06-27 2010-01-21 Shire International Licensing B.V. Combination of a lanthanum compound and bone enhancing agent for the treatment of bone diseases
US20100093772A1 (en) * 2004-08-04 2010-04-15 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
WO2010125572A1 (en) * 2009-04-29 2010-11-04 Hetero Research Foundation Compressed tablets and capsules containing efavirenz
EP1993513A4 (en) * 2006-03-14 2012-06-27 Merck Sharp & Dohme METHODS AND APPARATUS FOR PRODUCING CRYSTALLINE ORGANIC MICROPARTICLE COMPOSITIONS BY MICRO-GRAINING AND MICRO-GRAIN CRYSTALLIZATION AND USE THEREOF
US20140056955A1 (en) * 2010-12-27 2014-02-27 Dsm Ip Assets B.V. Powderous vitamin e formulations
US20140212488A1 (en) * 2012-05-01 2014-07-31 Althera Life Sciences Llc Oral tablet formulation consisting of immediate release rosuvastatin and extended release metformin
US20140275260A1 (en) * 2013-03-15 2014-09-18 Sanjay Rangnathrao Kawale Preparation Of Stable Pharmaceutical Dosage Forms
US20140350027A1 (en) * 2005-05-10 2014-11-27 Novartis Ag Pharmaceutical Compositions Comprising Imatinib and a Release Retardant
US9737488B2 (en) 2005-03-07 2017-08-22 Bayer Healthcare Llc Pharmaceutical composition for the treatment of cancer
CN114146089A (en) * 2021-12-15 2022-03-08 安徽贝克生物制药有限公司 Pharmaceutical composition containing efavirenz, tenofovir and emtricitabine
JP2023510055A (en) * 2020-01-21 2023-03-13 京東方科技集團股▲ふん▼有限公司 Support plate and folding display

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200400187T2 (en) * 1998-08-21 2006-11-21 Novartis Ag New oral formulation.
WO2003045327A2 (en) * 2001-11-27 2003-06-05 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
MXPA06000885A (en) * 2003-07-28 2006-05-04 Mallinckrodt Inc Improved stearate composition and method.
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
CN101262847B (en) 2005-09-12 2010-11-24 埃科特莱茵药品有限公司 Stable pharmaceutical compositions comprising pyrimidine-sulfonamides
ES2300188B1 (en) * 2006-05-24 2009-05-01 Ferrer Internacional, S.A. BICAPA COMPRESSED FOR THE PREVENTION OF CARDIOVASCULAR ACCIDENTS.
MX2010001837A (en) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd DERIVATIVES OF 4-PYRIMIDINASULFAMIDA.
CA2697150A1 (en) * 2007-08-17 2009-02-26 Teva Pharmaceutical Industries Ltd. Methods and compositions for controlling the bioavailability of poorly soluble drugs
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
EP2207533B1 (en) * 2007-10-10 2021-01-06 Avantor Performance Materials, LLC Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2344143A1 (en) * 2008-09-09 2011-07-20 Mukesh Harilal Shukla Bioactive composition for the treatment of the hiv/aids, method for manufacturing and using the same
EA201100851A1 (en) 2008-12-23 2012-04-30 Фармассет, Инк. NUCLEOSIDE ANALOGUES
EA019341B1 (en) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Nucleoside phosphoramidates
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
EP2253306A1 (en) * 2009-05-18 2010-11-24 Royal College of Surgeons in Ireland Orodispersible dosage forms containing solid drug dispersions
TWI576352B (en) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
WO2011036270A1 (en) * 2009-09-28 2011-03-31 Kerry Group Services International Limited Pharmaceutical composition
CA2778273A1 (en) * 2009-10-28 2011-05-12 Mcneil-Ppc, Inc. Fast dissolving/disintegrating coating compositions
WO2011055375A1 (en) * 2009-11-04 2011-05-12 Hetero Research Foundation Bioequivalent formulation of efavirenz
UY33312A (en) 2010-03-31 2011-10-31 Pharmasset Inc PURINE NUCLEOSIDE PHOSPHORAMIDATE
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
MX2012011171A (en) 2010-03-31 2013-02-01 Gilead Pharmasset Llc Nucleoside phosphoramidates.
JP6069215B2 (en) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー Compound
JP7202898B2 (en) * 2018-01-11 2023-01-12 沢井製薬株式会社 Film-coated orally disintegrating tablet

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2007764C (en) 1989-02-24 1999-11-30 Joseph Michael Beaurline Salsalate tablet
US5260073A (en) * 1990-05-21 1993-11-09 Norwich Eaton Pharmaceuticals, Inc. Use of phenylpropanolamine as a mucus secretogogue in the upper airways
HU217629B (en) 1991-12-12 2000-03-28 Novartis Ag. A method for the preparation of stabilized pharmaceutical compositions containing fluvastatin
US5663169A (en) * 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
AU1694295A (en) 1994-01-28 1995-08-15 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
US5663467A (en) 1995-01-23 1997-09-02 Merck & Co., Inc. Synthesis of cyclopropylacetylene
US5633405A (en) 1995-05-25 1997-05-27 Merck & Co., Inc. Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
US5874430A (en) * 1996-10-02 1999-02-23 Dupont Pharmaceuticals Company 4,4-disubstitued-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same
US5856492A (en) * 1997-01-10 1999-01-05 Merck & Co., Inc. Efficient synthesis of a chiral mediator
TW432028B (en) 1997-01-14 2001-05-01 Merck & Co Inc Asymmetric conjugate addition reaction using a chiral additive
US5998625A (en) * 1997-01-14 1999-12-07 Merck & Co., Inc. Asymmetric conjugate addition reaction using a chiral additive
AU738545C (en) 1997-02-05 2004-06-17 Merck Sharp & Dohme Corp. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
US5965729A (en) * 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
US5922864A (en) * 1997-02-12 1999-07-13 Merck & Co., Inc. Efficient synthesis of a 1,4-dihydro2H-3,1-benzoxazin-2-one
EP0979082A1 (en) 1997-05-17 2000-02-16 Glaxo Group Limited Antiviral combinations containing the carbocyclic nucleoside 1592u89
US6180634B1 (en) * 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
UA72207C2 (en) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Pharmaceutical formulations of efavirenz and disintegrants providing for increasing dissolution rate and process of manufacturing such tablets or capsules

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100015246A1 (en) * 2000-06-27 2010-01-21 Shire International Licensing B.V. Combination of a lanthanum compound and bone enhancing agent for the treatment of bone diseases
US20070116782A1 (en) * 2001-04-23 2007-05-24 Shire International Licensing B.V. Use of rare earth compounds for the prevention of kidney stone disease
US20100203133A1 (en) * 2002-04-23 2010-08-12 Novartis Ag High drug load tablet
EP1501485A1 (en) 2002-04-23 2005-02-02 Novartis AG High drug load tablet
WO2003090720A1 (en) 2002-04-23 2003-11-06 Novartis Ag High drug load tablet
US9011911B2 (en) 2002-04-23 2015-04-21 Novartis Ag High drug load tablet
US20050239679A1 (en) * 2002-10-18 2005-10-27 Solvay Interox Gmbh Method for producing dust-free alkaline earth peroxides
US7488439B2 (en) * 2002-10-18 2009-02-10 Solvay Chemicals Gmbh Method for producing dust-free alkaline earth peroxides
US8592397B2 (en) 2003-01-14 2013-11-26 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US8716264B2 (en) 2003-01-14 2014-05-06 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US9457036B2 (en) 2003-01-14 2016-10-04 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US20090036408A1 (en) * 2003-01-14 2009-02-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US20090143314A1 (en) * 2003-01-14 2009-06-04 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US9744181B2 (en) 2003-01-14 2017-08-29 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
US7465465B2 (en) 2003-08-26 2008-12-16 Shire Biochem Inc. Pharmaceutical formulation comprising lanthanum compounds
US20090017133A1 (en) * 2003-08-26 2009-01-15 Shire Biochem Inc. Pharmaceutical formulation comprising lanthanum compounds
US20080187602A1 (en) * 2003-08-26 2008-08-07 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
US20050079135A1 (en) * 2003-08-26 2005-04-14 Haslam Robert Paul Pharmaceutical formulation comprising lanthanum compounds
US20060121127A1 (en) * 2003-08-26 2006-06-08 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
US20060153932A1 (en) * 2004-07-27 2006-07-13 Shire Pharmaceuticals, Inc. Method of treating hyperphosphataemia using lanthanum hydroxycarbonate
US20100093772A1 (en) * 2004-08-04 2010-04-15 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
US20080268034A1 (en) * 2005-01-07 2008-10-30 Girish Karanth Solid Oral Dosage Forms of Ziprasidone Containing Colloidal Silicone Dioxide
US9737488B2 (en) 2005-03-07 2017-08-22 Bayer Healthcare Llc Pharmaceutical composition for the treatment of cancer
US20140350027A1 (en) * 2005-05-10 2014-11-27 Novartis Ag Pharmaceutical Compositions Comprising Imatinib and a Release Retardant
US20070077295A1 (en) * 2005-06-13 2007-04-05 Gilead Sciences, Inc. Method and composition for pharmaceutical product
US9545414B2 (en) * 2005-06-13 2017-01-17 Bristol-Myers Squibb & Gilead Sciences, Llc Unitary pharmaceutical dosage form
US20070099902A1 (en) * 2005-06-13 2007-05-03 Bristol-Myers Squibb & Gilead Sciences, Llc Unitary pharmaceutical dosage form
US8598185B2 (en) * 2005-06-13 2013-12-03 Bristol-Myers Squibb & Gilead Sciences, Inc. Unitary pharmaceutical dosage form
US20140037724A1 (en) * 2005-06-13 2014-02-06 Bristol-Myers Squibb & Gilead Sciences, Llc Unitary pharmaceutical dosage form
US20150174147A1 (en) * 2005-06-13 2015-06-25 Bristol-Myers Squibb & Gilead Sciences, Llc Unitary pharmaceutical dosage form
US9018192B2 (en) * 2005-06-13 2015-04-28 Bristol-Myers Squibb & Gilead Sciences, Inc. Unitary pharmaceutical dosage form
TWI471145B (en) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc Unitary pharmaceutical dosage form
US8871271B2 (en) 2005-06-13 2014-10-28 Gilead Sciences, Inc. Method and composition for pharmaceutical product
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
EP1993513A4 (en) * 2006-03-14 2012-06-27 Merck Sharp & Dohme METHODS AND APPARATUS FOR PRODUCING CRYSTALLINE ORGANIC MICROPARTICLE COMPOSITIONS BY MICRO-GRAINING AND MICRO-GRAIN CRYSTALLIZATION AND USE THEREOF
US20070259052A1 (en) * 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
US20100092576A1 (en) * 2006-05-05 2010-04-15 Shire International Licensing B.V. Pharmaceutical compositions containing lanthanum hydroxycarbonate
US7618656B2 (en) 2006-05-05 2009-11-17 Shire International Licensing B.V. Method for use of lanthanum carbonate pharmaceutical compositions
US20080089948A1 (en) * 2006-05-05 2008-04-17 Shire International Licensing B.V. Method of use for lanthanum carbonate and lanthanum hydroxycarbonate
WO2010125572A1 (en) * 2009-04-29 2010-11-04 Hetero Research Foundation Compressed tablets and capsules containing efavirenz
US20140056955A1 (en) * 2010-12-27 2014-02-27 Dsm Ip Assets B.V. Powderous vitamin e formulations
US10362800B2 (en) * 2010-12-27 2019-07-30 Dsm Ip Assets B.V. Powderous vitamin E formulations
US20140212488A1 (en) * 2012-05-01 2014-07-31 Althera Life Sciences Llc Oral tablet formulation consisting of immediate release rosuvastatin and extended release metformin
US20140275260A1 (en) * 2013-03-15 2014-09-18 Sanjay Rangnathrao Kawale Preparation Of Stable Pharmaceutical Dosage Forms
US10064826B2 (en) * 2013-03-15 2018-09-04 Navinta, Llc Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process
JP2023510055A (en) * 2020-01-21 2023-03-13 京東方科技集團股▲ふん▼有限公司 Support plate and folding display
CN114146089A (en) * 2021-12-15 2022-03-08 安徽贝克生物制药有限公司 Pharmaceutical composition containing efavirenz, tenofovir and emtricitabine

Also Published As

Publication number Publication date
US20020076436A1 (en) 2002-06-20
US7060294B2 (en) 2006-06-13
US20060188570A1 (en) 2006-08-24
US7595063B2 (en) 2009-09-29

Similar Documents

Publication Publication Date Title
US7060294B2 (en) Compressed tablet formulation
EP1083901B1 (en) Efavirenz compressed tablet formulation
US6696496B2 (en) Low water-soluble venlafaxine salts
EP2178511A2 (en) Tableted compositions containing atazanavir
WO2009002829A2 (en) Tableted compositions containing atazanavir
JP2016026222A (en) Tableted compositions containing atazanavir
EP1332757B1 (en) Efavirenz compressed tablet formulation
US6514529B2 (en) Oxazolidinone tablet formulation
EP1265608B1 (en) Oxazolidinone tablet formulation
EP2178512A2 (en) Tableted compositions containing atazanavir
WO2005016315A1 (en) Pharmaceutical compositions of nateglinide and a high amount of a water-soluble filler
EP1776102A1 (en) Preparations of stable pharmaceutical compositions of nateglinide and processes for their preparation
WO2005117840A1 (en) Stable pharmaceutical compositions comprising pulverized granules of nateglinide of form b

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION